Table 3 Secondary outcome in questionnaires.

From: The efficiency of azelastine hydrochloride and fluticasone propionate nasal spray to improve PAP adherence in patients with obstructive sleep apnea

Variables

Intervention (N = 49)

Placebo (N = 51)

P value

Total nasal symptom score

 First visit

4 (1, 6 )

3 (1, 4)

0.47

 Second visit

2 (0, 5)

3 (0, 5)

0.90

 Third visit

1 ( 0, 5)

3 (0, 5)

0.77

RQQ

 First visit

69.24 ± 30.95

63.27 ± 26.49

0.36

 Second visit

58.16 ± 28.55

53.47 ± 19.13

0.77

 Third visit

55.75 ± 29.77

52.52 ± 19.91

0.72

VAS

 First visit

9 (3, 24)

8 (2, 15)

0.36

 Second visit

4 (2, 17)

6 (2, 11)

0.77

 Third visit

4 (1, 16)

4 (2, 13)

0.50

  1. Data shown as mean ± SD or median (interquartile range).
  2. RQQ = Rhinoconjunctivitis Quality of Life Questionnaire, VAS = Visual analog scale.
Back to article page